Rituxan reduces risk of cancer recurrence, study shows

05/20/2010 | Bloomberg Businessweek

Biogen Idec and Genentech's Rituxan reduced the risk of follicular lymphoma recurrence by 50% during a late-stage trial in patients who respond to chemotherapy, according a study. Although the Rituxan group became prone to infection because of the drug, a study author said the treatment "is likely to become a new standard of care for these patients."

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC